NASDAQ:JAZZ • IE00B4Q5ZN47
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for JAZZ PHARMACEUTICALS PLC (JAZZ).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | Barclays | Initiate | Overweight |
| 2026-02-25 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-25 | B of A Securities | Maintains | Buy -> Buy |
| 2026-02-25 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-12 | Needham | Maintains | Buy -> Buy |
| 2026-01-12 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-11-24 | UBS | Downgrade | Buy -> Neutral |
| 2025-11-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-11-18 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-27 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-24 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-28 | Needham | Reiterate | Buy -> Buy |
| 2025-08-28 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-28 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-20 | Needham | Reiterate | Buy -> Buy |
| 2025-08-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-22 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.659B 18.27% | 3.834B 4.78% | 4.069B 6.12% | 4.323B 6.24% | 4.531B 4.81% | 4.878B 7.66% | 5.312B 8.90% | 5.831B 9.77% | 6.108B 4.75% | 5.854B -4.16% | 6.117B 4.49% | 6.214B 1.59% | |
| EBITDA YoY % growth | 738.4M -22.42% | 1.317B 78.37% | 1.387B 5.29% | 750.14M -45.90% | 2.155B 187.28% | 2.135B -0.93% | 2.397B 12.27% | 2.503B 4.42% | 2.699B 7.83% | 2.78B 3.00% | 2.971B 6.87% | 3.06B 3.00% | |
| EBIT YoY % growth | 108.9M -72.73% | 678.38M 522.94% | 726.63M 7.11% | 661.11M -9.02% | 1.775B 168.49% | 1.974B 11.21% | 2.107B 6.74% | 2.523B 19.74% | 2.576B 2.10% | 2.129B -17.35% | 2.4B 12.73% | 2.22B -7.50% | |
| Operating Margin | 2.98% | 17.69% | 17.86% | 15.29% | 39.17% | 40.47% | 39.66% | 43.27% | 42.17% | 36.37% | 39.23% | 35.73% | |
| EPS YoY % growth | 13.13 -19.10% | 18.32 39.53% | 21.19 15.67% | 8.36 -61.30% | 24.93 204.02% | 25.26 1.34% | 27.15 7.48% | 30.91 13.83% | 32.62 5.53% | 24.78 -24.04% | 27.11 9.42% | 23.38 -13.76% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 4.95 194.92% | 6.29 176.22% | 6.37 -21.70% | 6.98 5.12% |
| Revenue Q2Q % growth | 1.012B 12.71% | 1.127B 7.77% | 1.184B 5.14% | 1.246B 4.01% |
| EBITDA Q2Q % growth | 397.94M 265.15% | 501.46M -10.11% | 497.27M -19.42% | 564.22M 5.92% |
| EBIT Q2Q % growth | 351.93M 729.66% | 440.48M 101.16% | 516.41M 416.36% | 559.6M 11.26% |
All data in USD
23 analysts have analysed JAZZ and the average price target is 223.78 USD. This implies a price increase of 22.95% is expected in the next year compared to the current price of 182.01.
JAZZ PHARMACEUTICALS PLC (JAZZ) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of JAZZ PHARMACEUTICALS PLC (JAZZ) is 4.95 USD and the consensus revenue estimate is 1.01B USD.
The consensus rating for JAZZ PHARMACEUTICALS PLC (JAZZ) is 85.2174 / 100 . This indicates that analysts generally have a positive outlook on the stock.